Novel Amide Compounds With Longer Half-Life for CNS Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CNS therapeutic agents suffer from chronic toxicity, severe side effects, and inadequate pharmacokinetic properties such as short half-life, necessitating frequent administration and impacting patient compliance.
Innovation Solution
Development of novel amides with improved metabolic stability, longer half-life, and superior side effect profiles, exhibiting anticonvulsant, analgesic, and neuroprotective properties, which modulate CNS activity without complete suppression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If currently available CNS therapeutic agents are used, then good CNS activity is achieved, but chronic toxicity and severe side effects occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of amide compounds through specific substitutions (aromatic rings, heteroatoms, alkyl groups) to alter their pharmacological properties. This transforms the molecular parameters to achieve improved CNS activity while reducing toxicity and side effects compared to conventional agents
2Reliability
If currently available CNS therapeutic agents are used, then good CNS activity is achieved, but pharmacokinetic properties are inadequate with short half-life
Solution Approach 1:
The patent modifies pharmacokinetic parameters through structural changes to the amide compounds, specifically incorporating aromatic rings, heteroatoms, and various substituents that enhance metabolic stability and extend half-life, allowing for less frequent dosing while maintaining therapeutic effect
3Reliability
If frequent administration is required to sustain therapeutic concentrations, then therapeutic effect is maintained, but patient compliance decreases and therapy cost increases
Solution Approach 1:
The patent achieves continuous useful action by designing amide compounds with extended half-life and improved metabolic stability, allowing therapeutic concentrations to be maintained over longer periods. This enables less frequent dosing schedules while sustaining effective drug levels in the CNS
Data Source
AI summary
A series of novel amides showing broad pharmaceutical activity. Compounds described herein are effective as anticonvulsants, chemical countermeasures, and analgesics. Such compounds also show, neuroprotective/neuroreparative effects and activity against spinal muscular atrophy. Such pharmaceutically active compounds show utility in the treatment of central nervous system (“CNS”) diseases and disorders, such as anxiety, depression, insomnia, migraine headaches, schizophrenia, neurodegenerative diseases (e.g., Parkinson's disease, Alzheimer's, ALS, and Huntington's disease) spasticity, and bipolar disorder. Furthermore, such compounds may additionally find utility as analgesics (e.g., for the treatment of chronic or neuropathic pain) and as neuroprotective agents useful in the treatment of stroke(s), and/or traumatic brain and/or spinal cord injuries.